Aprea Therapeutics’ (APRE) “Buy” Rating Reaffirmed at HC Wainwright

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $20.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 430.50% from the stock’s previous close.

Aprea Therapeutics Trading Up 4.1 %

APRE stock traded up $0.15 during mid-day trading on Wednesday, reaching $3.77. 4,084 shares of the stock traded hands, compared to its average volume of 47,214. Aprea Therapeutics has a 52-week low of $2.15 and a 52-week high of $8.85. The stock’s fifty day moving average is $3.35 and its 200-day moving average is $3.46. The company has a market cap of $20.49 million, a P/E ratio of -1.34 and a beta of 0.75.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.11. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.45 million. Equities research analysts expect that Aprea Therapeutics will post -2.55 earnings per share for the current year.

Insider Activity

In related news, Director Marc Duey sold 6,462 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $4.58, for a total transaction of $29,595.96. Following the completion of the sale, the director now directly owns 233,651 shares in the company, valued at approximately $1,070,121.58. This trade represents a 2.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics comprises 0.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned approximately 2.53% of Aprea Therapeutics as of its most recent filing with the Securities & Exchange Commission. 34.19% of the stock is owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.